Medical expert of the article
New publications
Prevention and treatment of myelotoxic agranulocytosis in cancer patients
Last reviewed: 04.07.2025

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Myelotoxicity is the damaging effect of chemotherapy drugs on the hematopoietic tissue of the bone marrow. According to the criteria of the US National Cancer Institute, there are 4 degrees of suppression of each of the hematopoietic germs.
National Cancer Institute Myelotoxicity Criteria
Neutrophils |
Hemoglobin |
Platelets |
|
Degree 1 |
<2000-1500 per µl |
<120-100 g/l |
<150,000-75,000 per µl |
Degree 2 |
<1500-1000 per µl |
<100-80 g/l |
<75,000-50,000 per µl |
Degree 3 |
<1000-500 per µl |
<80-65 g/l |
<50,000-25,000 per µl |
Degree 4 |
<500 per µl |
<65 g/l |
<25,000 per µl |
Neutropenia is a serious manifestation of myelosuppression due to the high mortality from infectious complications that develop against its background. In this regard, the main task of an oncologist is to prevent the development of febrile neutropenia while maintaining the maximum intensity of chemotherapy. Currently, this can be achieved using cytokines G-CSF or filgrastim.
The administration of G-CSF (filgrastim) is the only way to reduce the duration and depth of myelotoxic neutropenia, as well as the development of febrile neutropenia. The administration of G-CSF before the first course of chemotherapy is called primary prevention of neutropenia, which is indicated for patients with the risk factors listed in the table.
Risk factors for the development of febrile neutropenia
Peculiarities of the patient's condition |
Features of the underlying disease |
Associated diseases |
Features of therapy |
Age >65 years |
Tumor lesion of bone marrow |
COPD |
History of severe neutropenia following similar courses of chemotherapy |
Female gender |
Common stages of the tumor process |
Cardiovascular diseases |
Use of anthracyclines |
Cachexia |
Elevated LDH levels (in lymphomas) |
Liver diseases |
Planned relative dose intensity >80% |
Immunodeficiency |
Oncohematological |
Diabetes mellitus |
Baseline neutropenia <1000/µL or lymphocytopenia |
Lung cancer | Low hemoglobin |
History of multiple chemotherapy courses |
|
Open wound surfaces |
Concurrent or prior use of radiation therapy to areas containing hematopoietic tissue | ||
Foci of infection |
Prescription of G-CSF preparations to patients with a history of prolonged profound neutropenia or an episode of febrile neutropenia after previous similar courses of chemotherapy is called secondary prevention. The MASSC screening system can be used to predict the outcome of febrile neutropenia in order to prescribe the most intensive etiotropic therapy and G-CSF preparations.
Screening system MASSC
Absence or mild symptoms of the disease |
5 |
No hypotension |
5 |
No COPD |
4 |
Solid tumor with no history of fungal infections |
4 |
No dehydration |
3 |
Moderate symptoms of the disease |
3 |
Outpatient regime |
3 |
Age <60 years |
2 |
Patients with a score of less than 21 are considered to be at high risk of adverse outcomes of febrile neutropenia. G-CSF preparations must be prescribed if neutropenia lasts more than 10 days, the neutrophil count is less than 100 per μl, and in patients over 65 years of age with progressive cancer, pneumonia, hypotension, sepsis, and invasive fungal infections. In addition, an absolute indication for G-CSF is hospitalization of a patient due to febrile neutropenia.
The standard dosage regimen of filgrastim for the prevention and treatment of myelotoxic neutropenia is 5.0 mcg/kg once daily intravenously or subcutaneously.
To achieve a stable therapeutic effect, it is necessary to continue G-CSF therapy until the absolute neutrophil count exceeds the expected minimum and does not exceed 2.0x10 9 /l. If necessary, the duration of the therapy course can be up to 12 days, depending on the severity of the disease and the severity of neutropenia. During the administration of cytokines, regular monitoring of the number of neutrophils in the patient's peripheral blood is necessary. It is important to administer G-CSF preparations at intervals of one day before or after taking antitumor cytostatic drugs due to the high sensitivity of actively proliferating myeloid cells to them.
G-CSF preparations are indicated for the treatment of neutropenia developing after high-dose myeloablative chemotherapy with autologous hematopoietic stem cell transplantation. In these cases, filgrastim is administered at a dose of 10 mcg/kg. After the moment of maximum decrease in the neutrophil count has passed, the daily dose is adjusted depending on the dynamics of their count. If the neutrophil content in the peripheral blood exceeds 1.0x10 9 /l for three consecutive days, the filgrastim dose is reduced by 2 times (to 5 mcg/kg). Then, if the absolute neutrophil count exceeds 1.0x10 9 /l for three consecutive days, filgrastim is discontinued. If the absolute neutrophil count decreases below 1.0x109 /l during treatment, the drug dose is again increased to 10 mcg/kg.
What tests are needed?